The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

By David Klatzmann, A. Abbas. Nature reviews. Immunology, 2015

613 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/82ac644a57a50a01d7d63e7790338c6b58818385

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. J. Buckner
2. J. Bluestone
3. Q. Tang
4. T. Hirano
5. J. Slots
6. Shimon Sakaguchi
7. P. Krammer
8. Angelika Schmidt

Citations in the corpus

• IL-6 in inflammation, autoimmunity and cancer (2020, background): “Accordingly, low-dose IL-2 therapy for autoimmune and inflammatory diseases is under development (199).”
• Type 1 diabetes immunotherapy using polyclonal regulatory T cells (2015, methodology): “The current efforts to use Treg-promoting therapies, such as low-dose IL-2 (38), are likely to be complementary to this current AT effort, potentially resulting in a robust combination therapy, which, when combined with Teff-depleting agents such as teplizumab and alefacept, may lead to durable remi”
• Periodontitis: facts, fallacies and the future. (2017, background): “Low-dose interleukin-2 (110), anti-tumor necrosis factor-alpha (173) and adoptive T-cell immunotherapy (34) have the potential to modulate dysregulated immunity in autoimmune and inflammatory diseases.”